서울대학교 중앙도서관

S-Space 소개

My S-Space

로그인이 필요합니다.

Login

S-Space

Browse

Subject

Jump to a point in the index

Or type in a year

Sort by
In order
Results/Page
Authors/record

Showing results 1 to 11 of 11

Issue Date	Title / Author(s) / Citation	File	Altmetrics
2016-07	Factors associated with late recurrence after completion of 5-year adjuvant tamoxifen in estrogen receptor positive breast cancer Lee, Eun-Shin; Han, Wonshik; Kim, Min Kyoon; Kim, Jongjin; Yoo, Tae-Kyung; Lee, Moo Hyun; Lee, Kyung Hun; Kim, Tae Yong; Moon, Hyeong-Gon; Im, Seock-Ah; Noh, Dong-Young; Lee, Eun Sook BMC Cancer, Vol.16, p. 430	view file DOI
2018-03	Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases Turner, N. C.; Finn, R. S.; Martin, M.; Im, S. -A; DeMichele, A.; Ettl, J.; Dieras, V.; Moulder, S.; Lipatov, O.; Colleoni, M.; Cristofanilli, M.; Lu, D. R.; Mori, A.; Giorgetti, C.; Iyer, S.; Bartlett, C. Huang; Gelmon, K. A. Annals of Oncology, Vol.29 No.3, pp.669-680	DOI
2018-06	Safety and antitumor activity of pembrolizumab in patients with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer Rugo, Hope S.; Delord, Jean-Pierre; Im, Seock-Ah; Ott, Patrick A.; Piha-Paul, Sarina A.; Bedard, Philippe L.; Sachdev, Jasgit; Le Tourneau, Christophe; van Brummelen, Emilie M. J.; Varga, Andrea; Salgado, Roberto; Loi, Sherene; Saraf, Sanatan; Pietrangelo, Dina; Karantza, Vassiliki; Tan, Antoinette R. Clinical Cancer Research, Vol.24 No.12, pp.2804-2811	DOI
2018-09	Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: A pooled analysis of randomised PALOMA clinical studies Rugo, Hope S.; Turner, Nicholas C.; Finn, Richard S.; Joy, Anil A.; Verma, Sunil; Harbeck, Nadia; Masuda, Norikazu; Im, Seock-Ah; Huang, Xin; Kim, Sindy; Sun, Wan; Iyer, Shrividya; Schnell, Patrick; Bartlett, Cynthia Huang; Johnston, Stephen European Journal of Cancer, Vol.101, pp.123-133	DOI
2018-11	Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3 Cristofanilli, Massimo; DeMichele, Angela; Giorgetti, Carla; Turner, Nicholas C.; Slamon, Dennis J.; Im, Seock-Ah; Masuda, Norikazu; Verma, Shailendra; Loi, Sherene; Colleoni, Marco; Theall, Kathy Puyana; Huang, Xin; Liu, Yuan; Bartlett, Cynthia Huang European Journal of Cancer, Vol.104, pp.21-31	DOI
2018-11	Overall survival with palbociclib and fulvestrant in advanced breast cancer Turner, Nicholas C.; Slamon, Dennis J.; Ro, Jungsil; Bondarenko, Igor; Im, Seock-Ah; Masuda, Norikazu; Colleoni, Marco; DeMichele, Angela; Loi, Sherene; Verma, Sunil; Iwata, Hiroji; Harbeck, Nadia; Loibl, Sibylle; Andre, Fabrice; Theall, K. Puyana; Huang, Xin; Giorgetti, Carla; Bartlett, C. Huang; Cristofanilli, Massimo New England Journal of Medicine, Vol.379 No.20, pp.1926-1936	DOI
2020-01	Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naive Metastatic Breast Cancer Finn, Richard S.; Liu, Yuan; Zhu, Zhou; Martin, Miguel; Rugo, Hope S.; Dieras, Veronique; Im, Seock-Ah; Gelmon, Karen A.; Harbeck, Nadia; Lu, Dongrui R.; Gauthier, Eric; Bartlett, Cynthia Huang; Slamon, Dennis J. Clinical Cancer Research, Vol.26 No.1, pp.110-121	DOI
2020-03	Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies Ettl, Johannes; Im, Seock-Ah; Ro, Jungsil; Masuda, Norikazu; Colleoni, Marco; Schnell, Patrick; Bananis, Eustratios; Lu, Dongrui R.; Cristofanilli, Massimo; Rugo, Hope S.; Finn, Richard S. Breast Cancer Research, Vol.22 No.1, p. 27	DOI
2022-07	Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer Modi, Shanu; Jacot, William; Yamashita, Toshinari; Sohn, Joohyuk; Vidal, Maria; Tokunaga, Eriko; Tsurutani, Junji; Ueno, Naoto T.; Prat, Aleix; Chae, Yee Soo; Lee, Keun Seok; Niikura, Naoki; Park, Yeon Hee; Xu, Binghe; Wang, Xiaojia; Gil-Gil, Miguel; Li, Wei; Pierga, Jean-Yves; Im, Seock-Ah; Moore, Halle C F; Rugo, Hope S.; Yerushalmi, Rinat; Zagouri, Flora; Gombos, Andrea; Kim, Sung-Bae; Liu, Qiang; Luo, Ting; Saura, Cristina; Schmid, Peter; Sun, Tao; Gambhire, Dhiraj; Yung, Lotus; Wang, Yibin; Singh, Jasmeet; Vitazka, Patrik; Meinhardt, Gerold; Harbeck, Nadia; Cameron, David A. New England Journal of Medicine, Vol.387 No.1, pp.9-20	DOI
2023-08	Olaparib efficacy in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer: Subgroup analyses from the phase III OlympiAD trial Senkus, Elzbieta; Delaloge, Suzette; Domchek, Susan M.; Conte, Pierfranco; Im, Seock-Ah; Xu, Binghe; Armstrong, Anne; Masuda, Norikazu; Fielding, Anitra; Robson, Mark; Tung, Nadine International Journal of Cancer, Vol.153 No.4, pp.1-12	DOI
2023-08	Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant Neven, P.; Fasching, P.A.; Chia, S.; Jerusalem, G.; De, Laurentiis M.; Im, S.-A.; Petrakova, K.; Bianchi, G.V.; Martin, M.; Nusch, A.; Sonke, G.S.; De, la Cruz-Merino L.; Beck, J.T.; Zarate, J.P.; Wang, Y.; Chakravartty, A.; Wang, C.; Slamon, D.J. Breast Cancer Research, Vol.25 No.1, p. 103	DOI

1